REV7 subunit of mutagenic DNA polymerase ζ as a predictive biomarker for the efficacy of immune checkpoint inhibitor therapy in melanoma
{{output}}
Immune checkpoint inhibitor (ICI) therapy serves as a standard treatment for advanced or recurrent malignant melanoma. Tumour neoantigenicity is an important factor for the effectiveness of the ICI therapy. However, the absence of reliable biomarkers to predic... ...
